| Code | CSB-RA025833MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Bevacizumab, targeting vascular endothelial growth factor A (VEGFA), a critical signaling protein that regulates angiogenesis and vascular permeability. VEGFA promotes endothelial cell proliferation, migration, and survival by binding to VEGF receptors on blood vessel surfaces, playing essential roles in both physiological and pathological neovascularization. Dysregulated VEGFA expression is implicated in numerous disease states, including various cancers where it facilitates tumor growth and metastasis through enhanced blood vessel formation, as well as ocular disorders such as age-related macular degeneration and diabetic retinopathy.
Bevacizumab, the reference antibody, is a humanized IgG1 monoclonal antibody that neutralizes VEGFA by preventing its interaction with cell surface receptors. This biosimilar provides researchers with a valuable tool for investigating VEGFA-mediated signaling pathways, angiogenesis mechanisms, and anti-angiogenic therapeutic strategies. It is suitable for studies examining tumor microenvironments, vascular biology, and the development of novel cancer therapeutics. This product supports reproducible experimental research in oncology, ophthalmology, and vascular disease models.
There are currently no reviews for this product.